Tagrisso
E505479
Tagrisso is a targeted cancer therapy (osimertinib) used primarily to treat certain types of EGFR-mutated non-small cell lung cancer.
All labels observed (2)
| Label | Occurrences |
|---|---|
| Tagrisso canonical | 2 |
| osimertinib | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5248760 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Tagrisso Context triple: [AstraZeneca, notableProduct, Tagrisso]
-
A.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
B.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
C.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
D.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
E.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Tagrisso Target entity description: Tagrisso is a targeted cancer therapy (osimertinib) used primarily to treat certain types of EGFR-mutated non-small cell lung cancer.
-
A.
Keytruda
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
B.
Ibrance
Ibrance is a targeted oral cancer medication (palbociclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
-
C.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
D.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
E.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
- F. None of above. chosen
Statements (50)
| Predicate | Object |
|---|---|
| instanceOf |
EGFR inhibitor
ⓘ
pharmaceutical drug ⓘ targeted cancer therapy ⓘ tyrosine kinase inhibitor ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| belongsToClass | third-generation EGFR tyrosine kinase inhibitors ⓘ |
| canPenetrate | blood–brain barrier ⓘ |
| developedBy | AstraZeneca ⓘ |
| FDAApprovalYear | 2015 ⓘ |
| hasActiveIngredient | osimertinib ⓘ |
| hasATCCode | L01EB10 ⓘ |
| hasBioavailability | high oral bioavailability ⓘ |
| hasBlackBoxWarning |
QT interval prolongation
ⓘ
interstitial lung disease ⓘ |
| hasChemicalFormula | C28H33N7O2 ⓘ |
| hasCommonAdverseEffect |
back pain
ⓘ
cough ⓘ decreased appetite ⓘ diarrhea ⓘ dry skin ⓘ fatigue ⓘ nausea ⓘ paronychia ⓘ pruritus ⓘ pyrexia ⓘ rash ⓘ stomatitis ⓘ |
| hasDosageForm | tablet ⓘ |
| hasHalfLife | approximately 48 hours ⓘ |
| hasInternationalNonproprietaryName | osimertinib ⓘ |
| hasLegalStatusInEU | prescription only ⓘ |
| hasLegalStatusInUS | prescription only ⓘ |
| hasPregnancyRisk | can cause fetal harm ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| indicatedFor |
EGFR-mutated non-small cell lung cancer
ⓘ
adjuvant treatment of EGFR-mutated non-small cell lung cancer after tumor resection ⓘ first-line treatment of EGFR-mutated metastatic non-small cell lung cancer ⓘ metastatic EGFR T790M-positive non-small cell lung cancer ⓘ non-small cell lung cancer ⓘ |
| isPrescriptionOnly | true ⓘ |
| isSmallMolecule | true ⓘ |
| isSubstrateOf |
CYP3A4
ⓘ
CYP3A5 ⓘ |
| mechanismOfAction | irreversible EGFR tyrosine kinase inhibitor ⓘ |
| targets |
EGFR L858R mutant
ⓘ
linked to:
EGFR
EGFR T790M mutant ⓘ EGFR exon 19 deletion mutant ⓘ epidermal growth factor receptor ⓘ
linked to:
EGFR
|
| usedFor | treatment of brain metastases in EGFR-mutated non-small cell lung cancer ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Tagrisso Description of subject: Tagrisso is a targeted cancer therapy (osimertinib) used primarily to treat certain types of EGFR-mutated non-small cell lung cancer.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.